Last reviewed · How we verify
NCT06086327
Application of 68Ga-Pentixafor PET/CT for Thymoma
EARLY_PHASE1 trial testing 68Ga-Pentixafor in Thymoma in 100 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 22 June 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-Pentixafor — full drug profile →
Conditions studied
- Thymoma — all drugs for Thymoma →
Sponsor
Peking Union Medical College Hospital
Who can join
18 and older, any sex, with Thymoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An Occult Primary Thymic Mucosa-Associated Lymphoid Tissue Lymphoma With Sjögren's Syndrome Revealed by CXCR4 Targeted <sup>68</sup>Ga-Pentixafor PET/CT.
Gao X, Peng X, Wang R, Qian Z, et al · · 2025 · cited 1× · PMID 39887860 · DOI 10.1111/jcmm.70248
Verify or expand the search:
- PubMed search for NCT06086327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 68Ga-Pentixafor
Trials testing the same drug.
- NCT07350707 — Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome · Phase 1, PHASE2 · recruiting
- NCT05188872 — Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE · NA · unknown
- NCT03436342 — Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma · EARLY_PHASE1 · unknown
Other recruiting trials for Thymoma
Currently open trials in the same condition.
- NCT06730308 — Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma · Phase 2 · recruiting
- NCT06692062 — Hypofractionated Radiotherapy for Thymic Epithelial Tumors · NA · recruiting
- NCT06029621 — Robot-assisted vs VATS for Thymoma · NA · recruiting
- NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting
- NCT05682742 — Clinical Investigation of the da Vinci Surgical System · NA · active not recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06086327 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06086327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing